The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies.
The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies.
复制标题
DOI：
10.3390/biomedicines9040389
复制
发表时间：
2021-04-06
期刊：
影响因子：
4.7
通讯作者：
Abdelrahim M
中科院分区：
文献类型：
--
作者：
Elsayed M;Abdelrahim M
胰腺导管腺癌（PDAC）是美国第四大癌症死亡原因，预计到2030年将成为第二大癌症死亡原因。缺乏有效的早期筛查试验和出现早期无法检测到的微转移的惊人症状是胰腺癌高死亡率的重要原因。除此之外，胰腺癌的低突变负担、低免疫学特征、致密的肿瘤发生基质以及肿瘤对细胞毒性药物的敏感性降低是PDAC患者生存率低的原因。尽管在化疗和免疫治疗药物方面取得了突破，但胰腺癌仍然是治愈率低下的实体肿瘤之一。因此，研究人员必须投入更多的精力来了解PDAC的病理和免疫行为，除了适当地利用更先进的筛查方式和新的治疗药物。在我们的综述中，我们主要关注临床指南的最新更新以及最近研究或正在研究的PDAC新疗法。我们使用PubMed作为搜索工具，查找原始研究文章，讨论诊断和治疗PDAC的最新进展。此外，我们还使用clinicaltrialsgov上发表的临床试验作为我们数据的来源。
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in the US, and it is expected to be the second leading cause of cancer deaths by 2030. The lack of effective early screening tests and alarming symptoms with early undetectable micro-metastasis at the time of presentation play a vital role in the high death rate from pancreatic cancer. In addition to this, the low mutation burden in pancreatic cancer, low immunological profile, dense tumorigenesis stroma, and decreased tumor sensitivity to cytotoxic drugs contribute to the low survival rates in PDAC patients. Despite breakthroughs in chemotherapeutic and immunotherapeutic drugs, pancreatic cancer remains one of the solid tumors that exhibit meager curative rates. Therefore, researchers must dedicate more effort to understanding the pathology and immunological behavior of PDAC, in addition to properly utilizing more advanced screening modalities and new therapeutic agents. In our review, we focus mainly on the latest updates from clinical guidelines and novel therapies that have been recently investigated or are under investigation for PDAC. We used PubMed as a search tool for finding original research articles addressing the latest developments in diagnosing and treating PDAC. Additionally, we also used the clinical trials published on clinicaltrialsgov as sources for our data.
登录
查看更多内容
影响因子：
3.2
作者：
Dhir M;Malhotra GK;Sohal DPS;Hein NA;Smith LM;O'Reilly EM;Bahary N;Are C
通讯作者：
Are C
影响因子：
64.8
作者：
Cabrita, Rita;Lauss, Martin;Jonsson, Goran
通讯作者：
Jonsson, Goran
影响因子：
6.2
作者：
Bria, Emilio;Milella, Michele;Giannarelli, Diana
通讯作者：
Giannarelli, Diana
影响因子：
29.4
作者：
Beatty GL;O'Hara MH;Lacey SF;Torigian DA;Nazimuddin F;Chen F;Kulikovskaya IM;Soulen MC;McGarvey M;Nelson AM;Gladney WL;Levine BL;Melenhorst JJ;Plesa G;June CH
通讯作者：
June CH
影响因子：
82.9
作者：
Binnewies M;Roberts EW;Kersten K;Chan V;Fearon DF;Merad M;Coussens LM;Gabrilovich DI;Ostrand-Rosenberg S;Hedrick CC;Vonderheide RH;Pittet MJ;Jain RK;Zou W;Howcroft TK;Woodhouse EC;Weinberg RA;Krummel MF
通讯作者：
Krummel MF